Health & Fitness
Health and Fitness
Health and Fitness
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009
Fri, June 26, 2009
Thu, June 25, 2009 Stem Cell Therapy International, Inc.: Stem Cell Therapy International, Inc. Announces the Distribution of Histostem Products
TAMPA, FL--(Marketwire - June 25, 2009) - Stem Cell Therapy International, Inc. (
In anticipation of the finalization of the merger between Stem Cell Therapy International, Inc. and Histostem, David Stark, SCTI President and CEO, has been working closely with Histostem management to prepare the supply channels and to network with various retailers to enable AmStem International, Inc. to begin US distribution and immediately bolster the company's cash flow. Details about the manufacturing and shipping of the Stem Cell Facial Cream, for example, have been worked out and are ready for implementation.
"The response to our Stem Cell Facial Cream has been extremely positive," informs Mr. Stark, "and because we have a proven market presence in Asia, proprietary supply chain, GMP-approved manufacturing facility, and some very promising study results, we are ready to partner with a major distributor right now."
AmStem International is also seeking investigators for a clinical study of the highest caliber, to compare its Stem Cell Facial Cream with others on the market. "Our experience with clinical trials is crucial," claims Mr. Stark. "We will be conducting a scientifically and statistically valid study, IRB-approved, and ethically sound. It will be conducted with GCP standards set by FDA, ICH, and other regulatory agencies. This study will compare our Stem Cell Facial Cream vs. inactive placebo and 3 competing products in a controlled, randomized protocol." He adds, "This is attracting leaders in the field as investigators, and we are confident that our study results will be phenomenal."
Stem Cell Therapy International, Inc. continues to work on the necessary steps to finalize the merger, and both sides are working diligently to manage its many details. "We will continue to collaborate closely with Histostem to ensure the greatest benefit for our stockholders and investors," adds Mr. Stark.
About Stem Cell Therapy International, Inc.
Stem Cell Therapy International, Inc. (
About AmStem International, Inc.
AmStem International, Inc. is a new biotechnology company based in Northern California, in the watershed of stem cell innovation fueled by President Obama's recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Further information about AmStem International, Inc. can be found by contacting David Stark, SCTI President, at the email posted below.
About Histostem Corporation, Ltd:
Histostem Co., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full-time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted and six patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. Further information about Histostem Corporation, Ltd. can be found by contacting David Stark, SCTI President, at the email posted below.
Forward-Looking Statements
Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Stem Cell Therapy International, Inc., may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, our ability to successfully complete the merger, successfully complete clinical trials; our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
